Research programme: proteolytic bacterial enzymes - Hansa Biopharam AB
Alternative Names: Endoglycosidase of Streptococcus pyogenes; EndoS; NiceR; Second generation IdeS; Second generation Ig-G-degrading enzyme of Streptococcus pyogenesLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Hansa Medical AB
- Developer Hansa Biopharma AB
- Class Anti-inflammatories; Antibacterials; Antineoplastics; Antirheumatics; Bacterial proteins; Enzymes; Immunotherapies
- Mechanism of Action Immunoglobulin modulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Transplant rejection
- Discontinued Rheumatoid arthritis; Streptococcal infections
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in Sweden (Parenteral)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Cancer in Sweden (Parenteral)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Transplant-rejection in Sweden (Parenteral)